Journal of Molecular and Cellular Cardiology
Volume 46, Issue 3 , Pages 289-291 , March 2009

Stable protein, unstable plaque?

Received 21 November 2008 ,Accepted 21 November 2008.

References 

  1. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993 Oct. 8;75(1):135–146
  2. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 1996;14:301–331
  3. Xu Y, Harton JA, Smith BD. CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules. J. Biol. Chem. 2008 Jan. 18;283(3):1243–1256
  4. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. 2006 Jul;6(7):508–519
  5. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 1997 Jun. 1;99(11):2752–2761
  6. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2003 Mar. 1;23(3):454–460
  7. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999 Jul;145(1):33–43
  8. Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ. Res. 1988 Oct;63(4):712–719
  9. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1995 Apr. 25;92(9):3893–3897
  10. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli SA. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 1999 Sep;155(3):775–786
  11. Lohler J, Timpl R, Jaenisch R. Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death. Cell. 1984 Sep;38(2):597–607
  12. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999 May 18;99(19):2503–2509
  13. Abdul-Hussien H, Soekhoe RG, Weber E, von der Thusen JH, Kleemann R, Mulder A, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am. J. Pathol. 2007 Mar;170(3):809–817
  14. Xu Y, Wang L, Buttice G, Sengupta PK, Smith BD. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J. Biol. Chem. 2004 Oct. 1;279(40):41319–41332
  15. Ting JP, Davis BK. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu. Rev. Immunol. 2005;23:387–414
  16. Sengupta P, Xu Y, Wang L, Widom R, Smith BD. Collagen alpha1(I) gene (COL1A1) is repressed by RFX family. J. Biol. Chem. 2005 Jun. 3;280(22):21004–21014
  17. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000 May 1;14(9):1156–1166
  18. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 2006 Sep;27(9):405–412
  19. Zika E, Greer SF, Zhu XS, Ting JP. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol. 2003 May;23(9):3091–3102
  20. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur. J. Immunol. 2003 Aug;33(8):2337–2347
  21. Greer SF, Zika E, Conti B, Zhu XS, Ting JP. Enhancement of CIITA transcriptional function by ubiquitin. Nat. Immunol. 2003 Nov;4(11):1074–1082
  22. Tosi G, Jabrane-Ferrat N, Peterlin BM. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J. 2002 Oct. 15;21(20):5467–5476
  23. Sisk TJ, Nickerson K, Kwok RP, Chang CH. Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. Int. Immunol. 2003 Oct;15(10):1195–1205
  24. Greer SF, Harton JA, Linhoff MW, Janczak CA, Ting JP, Cressman DE. Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation. J. Immunol. 2004 Jul. 1;173(1):376–383
  25. Voong LN, Slater AR, Kratovac S, Cressman DE. Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator. J. Biol. Chem. 2008 Apr. 4;283(14):9031–9039
  26. Spilianakis C, Papamatheakis J, Kretsovali A. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol. Cell. Biol. 2000 Nov;20(22):8489–8498
  27. Raval A, Weissman JD, Howcroft TK, Singer DS. The GTP-binding domain of class II transactivator regulates its nuclear export. J. Immunol. 2003 Jan. 15;170(2):922–930
  28. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity. 1996 Feb;4(2):167–178
  29. Xu Y, McDonald J, Perloff E, Buttice G, Schreiber BM, Smith BD. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice. Mol. Immunol. 2007 Mar;44(7):1709–1721
  30. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 2009 Mar;71(9):1–4
  31. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000 Dec.;6(12):1399–1402
  32. Lee SJ, Qin H, Benveniste EN. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur. J. Immunol. 2008 Aug.;38(8):2325–2336
  33. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 2008 Nov.;20(6):639–649
  34. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 2003 Aug. 1;278(31):28930–28937
  35. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006 Jan. 3;113(1):51–59
  36. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev., Drug Discov. 2007 Aug.;6(8):617–635
  37. Drazen JM. COX-2 inhibitors—a lesson in unexpected problems. N. Engl. J. Med. 2005 Mar. 17;352(11):1131–1132

PII: S0022-2828(08)01435-1

doi: 10.1016/j.yjmcc.2008.11.013

Journal of Molecular and Cellular Cardiology
Volume 46, Issue 3 , Pages 289-291 , March 2009

Article Tools